Step 1 topics → Hematology and Oncology → MGUS (Monoclonal Gammopathy of Undetermined Significance)

MGUS (Monoclonal Gammopathy of Undetermined Significance)

USMLE Step 1 trap: Ignores the quantitative thresholds that distinguish MGUS from smoldering or overt myeloma. MGUS requires M-protein < 3 g/dL, bone marrow plasma cells < 10%, and absence of CRAB end-organ damage.

MGUS is a premalignant plasma cell dyscrasia defined by a detectable M-protein spike on serum protein electrophoresis (SPEP) that falls below specific quantitative thresholds — and critically, causes no end-organ damage. The key framing for USMLE Step 1 is understanding where MGUS sits on the spectrum: it's not normal, it's not myeloma, and it's not smoldering myeloma. The exam will test whether you know the exact cutoffs that separate these entities and whether you can recognize that a patient with an M-spike doesn't automatically have myeloma.

Step 1 tests MGUS from two main angles. First, it gives you lab values and asks you to classify the condition — this requires knowing the thresholds cold: M-protein < 3 g/dL, bone marrow plasma cells < 10%, and absence of CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions). Second, it tests what you do with a MGUS diagnosis — the answer is monitor, not treat. The exam loves to bait students into over-managing this condition.

The tricky part is keeping three entities straight: MGUS, smoldering myeloma, and overt multiple myeloma. Students consistently conflate smoldering myeloma with MGUS, or assume any detectable M-spike means myeloma. Smoldering myeloma is the intermediate stage — higher M-protein (≥3 g/dL) or higher marrow plasma cells (10–60%), but still no CRAB damage and still no treatment. These distinctions are entirely threshold-based, which means you have to memorize the numbers, not just the concept.

From real student decks
49%have cards covering this topic
30%have mature cards

Common misconceptions

Common mistake
Wrong: Any detectable M-spike on SPEP qualifies as MGUS regardless of size.
Right: MGUS requires M-protein < 3 g/dL, bone marrow plasma cells < 10%, and absence of CRAB end-organ damage.
A detectable M-spike alone does not make a diagnosis of MGUS — size and context matter. MGUS is specifically defined by M-protein below 3 g/dL, bone marrow plasma cells below 10%, and the complete absence of CRAB end-organ damage. If any of these thresholds are exceeded, you're no longer dealing with MGUS; you're dealing with smoldering or overt myeloma, and the distinction has major management implications.
Common mistake
Wrong: MGUS frequently and rapidly progresses to myeloma, warranting immediate treatment.
Right: MGUS progresses to myeloma or related disorder at approximately 1% per year; it requires monitoring but no treatment.
MGUS feels scary because it's a plasma cell dyscrasia, but the actual progression rate to myeloma is only about 1% per year — meaning most patients with MGUS will never develop myeloma in their lifetime. This is why MGUS is managed with watchful waiting and periodic monitoring (repeat SPEP, CBC, creatinine), not chemotherapy or any active treatment. Treating MGUS would cause more harm than the disease itself.
Common mistake
Wrong: Smoldering myeloma is just another name for MGUS.
Right: Smoldering myeloma has higher M-protein (≥3 g/dL) or marrow plasma cells (10–60%) than MGUS but still lacks CRAB end-organ damage.
Smoldering myeloma is a distinct intermediate entity, not a synonym for MGUS. The difference is quantitative: smoldering myeloma requires M-protein ≥3 g/dL or bone marrow plasma cells between 10–60%, which are exactly the thresholds where MGUS ends. Both MGUS and smoldering myeloma lack CRAB end-organ damage, but smoldering myeloma carries a higher risk of progression and different follow-up intensity — they are not interchangeable terms.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the three criteria that define MGUS: M-protein < 3 g/dL on SPEP, bone marrow plasma cells < 10%, and no CRAB end-organ damage (hyperCalcemia, Renal failure, Anemia, Bone lesions) — all three must be met simultaneously.
  2. Understand the natural history of MGUS: it progresses to myeloma or a related disorder at approximately 1% per year, which means monitoring (not treatment) is the appropriate management strategy.

Can you avoid these mistakes?

A 67-year-old man has an M-protein of 1.8 g/dL on SPEP, bone marrow biopsy showing 7% plasma cells, normal calcium, creatinine, hemoglobin, and no lytic lesions on skeletal survey. What is the diagnosis, and what is the next step in management?
A patient's SPEP shows an M-spike of 3.4 g/dL. Bone marrow biopsy shows 15% plasma cells. She has no hypercalcemia, her creatinine is normal, hemoglobin is 13.5 g/dL, and skeletal survey is negative. How does this differ from MGUS, and what is the diagnosis?
You see a 72-year-old woman with MGUS diagnosed 5 years ago. Her M-protein has been stable at 1.2 g/dL. A medical student suggests starting treatment to prevent progression to myeloma. What is the correct response, and why?
A patient with a newly detected M-spike on SPEP asks you what the chance is that this will turn into myeloma. What do you tell them about the annual progression rate, and how does this inform your management plan?

Related topics

Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →